# AMN Healthcare Services Inc: Form 10-Q for the period ended Jun 30, 2022

- Company: [AMN Healthcare Services Inc](/companies/amn.md) (CIK 1142750)
- Form: 10-Q
- Filed: 2022-08-05
- Accepted by EDGAR: Aug 5, 2022, 16:16 ET
- Period: 2022-06-30
- Accession: 0001142750-22-000023
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1142750/000114275022000023/amn-20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1142750/000114275022000023/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $1.43bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $2.98bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $966.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $2.02bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-04-01 to 2022-06-30 | $460.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-01-01 to 2022-06-30 | $956.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2022-04-01 to 2022-06-30 | $244.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2022-01-01 to 2022-06-30 | $502.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | $183.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | $391.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-04-01 to 2022-06-30 | $10.1m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2022-01-01 to 2022-06-30 | $19.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $49.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $102.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | $123.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | $269.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $2.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $5.87 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $2.78 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $5.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 44,740,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 45,972,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | $424.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $30.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2022-01-01 to 2022-06-30 | $401.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-06-30 | $79.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $1.19bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $3.01bn | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $957.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $1.97bn | us-gaap:Liabilities |
| Shareholders' equity | at 2022-06-30 | $1.04bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 42,784 characters.

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 (“2021 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

### Overview of Our Business

We provide healthcare workforce solutions and staffing services to healthcare organizations across the nation. As an innovative total talent solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” workforce consulting services, predictive modeling, staff scheduling, credentialing services, revenue cycle solutions, language services, and the placement of physicians, nurses, allied healthcare professionals and healthcare leaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.

We conduct business through three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. For the three months ended June 30, 2022, we recorded revenue of $1,426.6 million, as compared to $857.4 million for the same period last year. For the six months ended June 30, 2022, we recorded revenue of $2,979.1 million, as compared to $1,743.4 million for the same period last year.

Nurse and allied solutions segment revenue comprised 78% and 74% of total consolidated revenue for the six months ended June 30, 2022 and 2021, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all of the temporary nursing and allied staffing needs of a client. We also provide revenue cycle solutions, which include skilled labor solutions for remote medical coding, clinical documentation improvement, case management, and clinical data registry, and provide auditing and advisory services. A majority of our placements in this segment are under our managed services solution, however, we also provide traditional direct nurse and allied healthcare staffing solutions of variable assignment lengths.

Physician and leadership solutions segment revenue comprised 12% and 16% of total consolidated revenue for the six months ended June 30, 2022 and 2021, respectively. Through our physician and leadership solutions segment, we place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis, generally as independent contractors. We also recruit physicians and healthcare leaders for permanent placement and place interim leaders and executives across all healthcare settings. The interim healthcare leaders and executives we place are typically placed on contracts with assignment lengths ranging from a few days to one year, and a growing number of these placements are under our managed services solution.

Technology and workforce solutions segment revenue comprised 10% of total consolidated revenue for both of the six months ended June 30, 2022 and 2021. Through our technology and workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) language services, (2) software-as-a-service (“SaaS”) VMS technologies through which our clients can manage their temporary staffing needs, (3) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, (4) recruitment process outsourcing services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, (5) virtual care services, and (6) credentialing services.

As part of our long-term growth strategy to add value for our clients, healthcare professionals, and shareholders, on May 13, 2022 and April 7, 2021, we acquired Connetics and Synzi (including its wholly-owned subsidiary SnapMD), respectively. Connetics specializes in the direct hire recruitment and permanent placement of international nurse and allied health professionals with healthcare facilities in the United States. Synzi and SnapMD offer virtual care technology platforms; Synzi focuses on the care management and home health markets and primarily serves as a patient communication and engagement platform, while SnapMD focuses on the outpatient market and primarily serves as a clinical communication and documentation platform. See additional information in the accompanying Note (2), “Acquisitions.”

### Operating Metrics

In addition to our consolidated and segment financial results, we monitor the following key metrics to help us evaluate our results of operations and financial condition and make strategic decisions. We believe this information is useful in understanding our operational performance and trends affecting our businesses.

- Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period, which is used by management as a measure of volume in our nurse and allied solutions segment;
- Bill rates represent the hourly straight-time rates that we bill to clients, which are an indicator of labor market trends and costs within our nurse and allied solutions segment;
- Billable hours represent hours worked by our healthcare professionals that we are able to bill on client engagements, which are used by management as a measure of volume in our nurse and allied solutions segment;
- Days filled is calculated by dividing total locum tenens hours filled during the period by eight hours, which is used by management as a measure of volume in our locum tenens business within our physician and leadership solutions segment; and
- Revenue per day filled is calculated by dividing revenue of our locum tenens business by days filled for the period, which is an indicator of labor market trends and costs in our locum tenens business within our physician and leadership solutions segment.

### Recent Trends

Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends, and since early 2020 through present, the COVID-19 pandemic and the “Great Resignation” have impacted demand. Since late 2020, we have been experiencing historically high demand for nurses and allied healthcare professionals and demand across all segments and business lines is above pre-COVID-19 levels.

Our clients continue to face labor shortages resulting from burnout, attrition, and retirements, resulting in high demand levels across our nurse and allied solutions segment. After another COVID-related surge in the first quarter, travel nurse demand is approaching new normal levels, though still above pre-pandemic levels. Demand in our allied staffing division declined from the all-time high in the first quarter, and remains strong and well-above pre-pandemic levels. The wages for nurses and the corresponding bill rates we charge our clients peaked in the first quarter of 2022 due to the higher demand amidst a clinical labor shortage and our clients’ need to frequently fill positions quickly. Bill rates and clinician compensation declined in the second quarter, but remain well above pre-pandemic levels. We expect bill rates and clinician compensation to decline further in the third quarter and stabilize well above pre-pandemic levels as we exit 2022.

In our physician and leadership solutions segment, demand recovered in the first quarter of 2022 and exceeds pre-pandemic levels. Compared to the first quarter of 2022, we saw a decline in COVID-19 project demand, which was partially offset by strong core demand for our locum tenens and interim leadership businesses. Longer term, we expect continued strong demand resulting from an increased level of burnout and turnover of healthcare leadership roles.

In our technology and workforce solutions segment, our language services business continued to experience increased utilization due to a shift to more virtual interpretation during the pandemic and labor shortages. Bill rates and volumes declined in our VMS business after another COVID surge in the first quarter, but still remained well above pre-pandemic levels. We anticipate bill rates will continue to decline in the third quarter before stabilizing well above pre-pandemic levels towards the end of 2022.

The demand for our recruitment process outsourcing services remained strong as clients look for solutions to help address the increased labor shortages and the need to address vacancies in their permanent roles and challenges with staffing their internal recruiting teams. We expect an elevated level of demand to continue in the current constrained labor market.

As our businesses have continued to grow, we have increased our sales and operations workforce to support our clients and healthcare professionals. We have also increased spending to support our current team members and retain talent.

### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, contingent consideration (“earn-out”) liabilities associated with acquisitions, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2021 Annual Report.

### Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The Connetics and Synzi acquisitions impact the comparability of the results between the three and six months ended June 30, 2022 and 2021, depending on the timing of the applicable acquisition. Our historical results are not necessarily indicative of our future results of operations.

*Unaudited Condensed Consolidated Statements of Operations:*

|  | Three Months Ended June 30, 2022 | 2021 | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of revenue | 67.7 | 67.3 | 67.9 | 67.3 |
| Gross profit | 32.3 | 32.7 | 32.1 | 32.7 |
| Selling, general and administrative | 17.1 | 18.3 | 16.9 | 18.2 |
| Depreciation and amortization | 2.3 | 2.8 | 2.1 | 2.8 |
| Income from operations | 12.9 | 11.6 | 13.1 | 11.7 |
| Interest expense, net, and other | 0.7 | 1.2 | 0.6 | 1.1 |
| Income before income taxes | 12.2 | 10.4 | 12.5 | 10.6 |
| Income tax expense | 3.5 | 2.6 | 3.4 | 2.7 |
| Net income | 8.7% | 7.8% | 9.1% | 7.9% |

### Comparison of Results for the Three Months Ended June 30, 2022 to the Three Months Ended June 30, 2021

***Revenue.*** Revenue increased 66% to $1,426.6 million for the three months ended June 30, 2022 from $857.4 million for the same period in 2021, primarily attributable to higher organic revenue across our segments.

Nurse and allied solutions segment revenue increased 76% to $1,101.5 million for the three months ended June 30, 2022 from $624.5 million for the same period in 2021. The $477.0 million increase was primarily attributable to a 31% increase in the average number of travelers on assignment, an approximately 31% increase in the average bill rate, and an approximately $81.0 million increase in labor disruption revenue during the three months ended June 30, 2022. The overall increase was partially offset by a 3% decrease in billable hours.

Physician and leadership solutions segment revenue increased 26% to $175.7 million for the three months ended June 30, 2022 from $139.1 million for the same period in 2021. The $36.6 million increase was primarily attributable to growth across businesses within the segment. Revenue in our locum tenens business grew approximately 36% during the three months ended June 30, 2022 primarily due to a 25% increase in the number of days filled and a 9% increase in the revenue per day filled. This growth was driven by a return in core demand and volume. Our interim leadership business experienced an approximately 8% growth, while our physician permanent placement and executive search businesses grew 28% during the three months ended June 30, 2022.

Technology and workforce solutions segment revenue increased 59% to $149.4 million for the three months ended June 30, 2022 from $93.9 million for the same period in 2021. The $55.5 million increase was primarily attributable to growth within our VMS, language services and outsourced solutions businesses. Revenue growth for our VMS and language services businesses was 144% and 17%, respectively, during the three months ended June 30, 2022.

For the three months ended June 30, 2022 and 2021, revenue under our MSP arrangements comprised approximately 60% and 58% of our consolidated revenue, 75% and 75% of our nurse and allied solutions segment revenue, 17% and 15% of our physician and leadership solutions segment revenue, and 1% and 2% of our technology and workforce solutions segment revenue, respectively.

***Gross Profit.*** Gross profit increased 64% to $460.2 million for the three months ended June 30, 2022 from $280.5 million for the same period in 2021, representing gross margins of 32.3% and 32.7%, respectively. The decline in consolidated gross margin for the three months ended June 30, 2022, as compared to the same period in 2021, was primarily due to (1) a lower margin in our nurse and allied solutions segment driven by higher clinician compensation and a decrease in billable hours, (2) a change in sales mix resulting from higher revenue in our nurse and allied solutions segment, and (3) a lower margin in our physician and leadership solutions segment driven by higher clinician compensation and a change in specialty mix in our locum tenens business. The overall decline was partially offset by a higher margin in our technology and workforce solutions segment primarily due to a change in sales mix resulting from increased revenue in our VMS business and its higher margins as compared to our other businesses within the segment. Gross margin by reportable segment for the three months ended June 30, 2022 and 2021 was 25.7% and 26.6% for nurse and allied solutions, 34.2% and 36.6% for physician and leadership solutions, and 78.3% and 67.7% for technology and workforce solutions, respectively.

***Selling, General and Administrative Expenses.*** Selling, general and administrative (“SG&A”) expenses were $244.4 million, representing 17.1% of revenue, for the three months ended June 30, 2022, as compared to $156.6 million, representing 18.3% of revenue, for the same period in 2021. The increase in SG&A expenses was primarily due to higher employee compensation and benefits and other expenses associated with our revenue growth. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

*(In Thousands)*

|  | Three Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Nurse and allied solutions | $122,426 | $76,487 |
| Physician and leadership solutions | 40,010 | 29,014 |
| Technology and workforce solutions | 35,408 | 21,482 |
| Unallocated corporate overhead | 38,073 | 23,627 |
| Share-based compensation | 8,513 | 6,019 |
|  | $244,430 | $156,629 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 29% to $20.4 million for the three months ended June 30, 2022 from $15.8 million for the same period in 2021, primarily attributable to (1) the assignment of useful lives to certain tradenames and trademarks intangible assets that were previously not subject to amortization effective December 31, 2021 and (2) additional amortization expenses related to the intangible assets acquired in the Connetics acquisition. Depreciation expense (exclusive of depreciation included in cost of revenue) increased 35% to $12.0 million for the three months ended June 30, 2022 from $8.9 million for the same period in 2021, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing information technology investments to support our total talent solutions initiatives and to optimize our internal systems. Additionally, $1.0 million and $0.6 million of depreciation expense for our language services business is included in cost of revenue for the three months ended June 30, 2022 and 2021, respectively.

***Interest Expense, Net, and Other.*** Interest expense, net, and other was $10.1 million during the three months ended June 30, 2022 as compared to $10.1 million for the same period in 2021. The slight decrease was primarily due to a lower average debt outstanding balance during the three months ended June 30, 2022, which resulted from repayments of our credit facilities.

***Income Tax Expense.*** Income tax expense was $49.7 million for the three months ended June 30, 2022 as compared to $22.3 million for the same period in 2021, reflecting effective income tax rates of 29% and 25% for these periods, respectively. The increase in the effective income tax rate was primarily attributable to the recognition of $4.1 million of discrete tax expense for fair value changes in the cash surrender value of our Company Owned Life Insurance (“COLI”) during the three months ended June 30, 2022 compared to a $1.1 million discrete tax benefit for COLI recognized during the same period in 2021, in relation to income before income taxes of $173.5 million and $89.1 million for the three months ended June 30, 2022 and 2021, respectively. We currently estimate our annual effective tax rate to be approximately 27% for 2022. The 29% effective tax rate for the three months ended June 30, 2022 differs from our estimated annual effective tax rate of 27% primarily due to the discrete tax expense for COLI recognized during the three months ended June 30, 2022, in relation to income before income taxes.

### Comparison of Results for the Six Months Ended June 30, 2022 to the Six Months Ended June 30, 2021

***Revenue.*** Revenue increased 71% to $2,979.1 million for the six months ended June 30, 2022 from $1,743.4 million for the same period in 2021, primarily attributable to higher organic revenue across our segments.

Nurse and allied solutions segment revenue increased 82% to $2,329.5 million for the six months ended June 30, 2022 from $1,281.1 million for the same period in 2021. The $1,048.4 million increase was primarily attributable to an approximately 36% increase in the average number of travelers on assignment, a 33% increase in the average bill rate, and an approximately $81.0 million increase in labor disruption revenue during the six months ended June 30, 2022. The overall increase was partially offset by a 2% decrease in billable hours.

Physician and leadership solutions segment revenue increased 27% to $355.2 million for the six months ended June 30, 2022 from $279.9 million for the same period in 2021. The $75.3 million increase was primarily attributable to growth across businesses within the segment. Revenue in our locum tenens business grew approximately 33% during the six months ended June 30, 2022 primarily due to a 27% increase in the number of days filled and a 5% increase in the revenue per day filled. This growth was driven by a return in core demand and volume. Our interim leadership business experienced an approximately 11% growth, while our physician permanent placement and executive search businesses grew 36% during the six months ended June 30, 2022.

Technology and workforce solutions segment revenue increased 61% to $294.4 million for the six months ended June 30, 2022 from $182.4 million for the same period in 2021. The $112.0 million increase was primarily attributable to growth within our VMS, language services, and outsourced solutions businesses during the six months ended June 30, 2022. Revenue growth for our VMS and language services businesses was 140% and 18%, respectively, during the six months ended June 30, 2022.

For the six months ended June 30, 2022 and 2021, revenue under our MSP arrangements comprised approximately 64% and 58% of our consolidated revenue, 80% and 75% of our nurse and allied solutions segment revenue, 17% and 14% of our physician and leadership solutions segment revenue, and 2% and 1% of our technology and workforce solutions segment revenue, respectively.

***Gross Profit.*** Gross profit increased 68% to $956.4 million for the six months ended June 30, 2022 from $569.4 million for the same period in 2021, representing gross margins of 32.1% and 32.7%, respectively. The decline in consolidated gross margin for the six months ended June 30, 2022, as compared to the same period in 2021, was primarily due to (1) a lower margin in our nurse and allied solutions segment driven by higher clinician compensation, (2) a change in sales mix resulting from higher revenue in our nurse and allied solutions segment, and (3) a lower margin in our physician and leadership solutions segment driven by higher clinician compensation and a change in specialty mix in our locum tenens business. The overall decline was partially offset by a higher margin in our technology and workforce solutions segment primarily due to a change in sales mix resulting from increased revenue in our VMS business and its higher margins as compared to our other businesses within the segment. Gross margin by reportable segment for the six months ended June 30, 2022 and 2021 was 26.0% and 26.8% for nurse and allied solutions, 34.6% and 36.8% for physician and leadership solutions, and 77.5% and 67.7% for technology and workforce solutions, respectively.

***Selling, General and Administrative Expenses.*** SG&A expenses were $502.0 million, representing 16.9% of revenue, for the six months ended June 30, 2022, as compared to $317.8 million, representing 18.2% of revenue, for the same period in 2021. The increase in SG&A expenses was primarily due to higher employee compensation and benefits and other expenses associated with our revenue growth. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

*(In Thousands)*

|  | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Nurse and allied solutions | $249,422 | $151,857 |
| Physician and leadership solutions | 82,499 | 59,829 |
| Technology and workforce solutions | 68,595 | 39,801 |
| Unallocated corporate overhead | 81,721 | 51,048 |
| Share-based compensation | 19,772 | 15,306 |
|  | $502,009 | $317,841 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 29% to $40.0 million for the six months ended June 30, 2022 from $31.0 million for the same period in 2021, primarily attributable to (1) the assignment of useful lives to certain tradenames and trademarks intangible assets that were previously not subject to amortization effective December 31, 2021 and (2) additional amortization expenses related to the intangible assets acquired in the Connetics and Synzi acquisitions. Depreciation expense (exclusive of depreciation included in cost of revenue) increased 35% to $23.0 million for the six months ended June 30, 2022 from $17.0 million for the same period in 2021, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing information technology investments to support our total talent solutions initiatives and to optimize our internal front and back-office systems. Additionally, $1.8 million and $1.1 million of depreciation expense for our language services business is included in cost of revenue for the six months ended June 30, 2022 and 2021, respectively.

***Interest Expense, Net, and Other.*** Interest expense, net, and other was $19.7 million during the six months ended June 30, 2022 as compared to $19.1 million for the same period in 2021. The increase was primarily due to a $1.3 million gain related to the change in fair value of an equity investment during the six months ended June 30, 2021. The overall increase was partially offset by a lower average debt outstanding balance during the six months ended June 30, 2022, which resulted from repayments of our variable rate credit facilities.

***Income Tax Expense.*** Income tax expense was $102.0 million for the six months ended June 30, 2022 as compared to $47.4 million for the same period in 2021, reflecting effective income tax rates of 27% and 26% for the six months ended June 30, 2022 and 2021, respectively. The increase in the effective income tax rate was primarily attributable to the recognition of $1.7 million of net discrete tax expense during the six months ended June 30, 2022 compared to $3.5 million of net discrete tax benefits recognized during the same period in 2021, in relation to income before income taxes of $371.8 million and $184.5 million for the six months ended June 30, 2022 and 2021, respectively.

### Liquidity and Capital Resources

In summary, our cash flows were:

*(In Thousands)*

|  | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $424,677 | $210,625 |
| Net cash used in investing activities | (115,762) | (53,609) |
| Net cash used in financing activities | (411,688) | (30,703) |

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities. As of June 30, 2022, (1) no amount was drawn with $378.6 million of available credit under our $400.0 million secured revolving credit facility (the “Senior Credit Facility”), (2) the aggregate principal amount of our 4.625% senior notes due 2027 (the “2027 Notes”) outstanding was $500.0 million, and (3) the aggregate principal amount of our 4.000% senior notes due 2029 (the “2029 Notes”) outstanding was $350.0 million. We describe in further detail our amended credit agreement, under which the Senior Credit Facility is governed, the 2027 Notes, and the 2029 Notes in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2021 Annual Report.

As of June 30, 2022, the total of our contractual obligations under operating leases with initial terms in excess of one year was $20.7 million. We describe in further detail our operating lease arrangements in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (5), Leases” of our 2021 Annual Report. We also have various obligations and working capital requirements, such as certain tax and legal matters, contingent consideration and other liabilities, that are recorded on our consolidated balance sheets. See additional information in the accompanying Note (6), “Fair Value Measurement,” Note (7), “Income Taxes,” Note (8), “Commitments and Contingencies,” and Note (9), “Balance Sheet Details.”

In addition to our cash requirements, we have a share repurchase program authorized by our board of directors, which does not require the purchase of any minimum number of shares and may be suspended or discontinued at any time. See additional information in the accompanying Part II, Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds.”

We believe that cash generated from operations and available borrowings under the Senior Credit Facility will be sufficient to fund our operations and liquidity requirements, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under the Senior Credit Facility or other borrowings under our amended credit agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

### Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2022 was $424.7 million, compared to $210.6 million for the same period in 2021. The increase in net cash provided by operating activities was primarily attributable to (1) an increase in net income excluding non-cash expenses of $178.3 million primarily due to improved operating results in our nurse and allied solutions and technology and workforce solutions segments, (2) a decrease in accounts receivable and subcontractor receivables between periods of $136.8 million due to a smaller increase in the receivables balance during the six months ended June 30, 2022, which was primarily due to increases in revenue and associate vendor usage during 2021, and (3) a decrease in prepaid expenses between periods of $49.3 million primarily due to refunds received for prepayments to third-party vendors related to labor disruption services. The overall increase in net cash provided by operating activities was partially offset by (1) a decrease in other liabilities between periods of $99.0 million primarily due to cash paid for income taxes and client deposits related to labor disruption services that were returned during the six months ended June 30, 2022 and (2) a decrease in accounts payable and accrued expenses between periods of $62.4 million primarily due to a smaller increase in associate vendor usage during the six months ended June 30, 2022. Our Days Sales Outstanding (“DSO”) was 50 days at June 30, 2022, 53 days at December 31, 2021, and 50 days at June 30, 2021.

### Investing Activities

Net cash used in investing activities for the six months ended June 30, 2022 was $115.8 million, compared to net cash used in investing activities of $53.6 million for the same period in 2021. The increase was primarily due to (1) $69.8 million used for acquisitions during the six months ended June 30, 2022, as compared to $41.3 million during the six months ended June 30, 2021, and (2) a net purchase of investments of $1.6 million during the six months ended June 30, 2022, as compared to net proceeds of $12.7 million during the six months ended June 30, 2021. In addition, capital expenditures were $30.8 million and $23.1 million for the six months ended June 30, 2022 and 2021, respectively.

### Financing Activities

Net cash used in financing activities during the six months ended June 30, 2022 was $411.7 million due to $401.9 million paid in connection with the repurchase of our common stock and $9.8 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards. Net cash used in financing activities during the six months ended June 30, 2021 was $30.7 million, primarily due to (1) repayments of $70.0 million under the Senior Credit Facility and $21.9 million under our then-existing secured term loan credit facility, (2) $5.7 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards, and (3) $3.1 million for acquisition earn-out payments, partially offset by borrowings of $70.0 million under the Senior Credit Facility.

### Letters of Credit

At June 30, 2022, we maintained outstanding standby letters of credit totaling $22.0 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $22.0 million of outstanding letters of credit, we have collateralized $0.6 million in cash and cash equivalents and the remaining $21.4 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2021 totaled $23.6 million.

### Recent Accounting Pronouncements

In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The new guidance will require companies to apply the definition of a performance obligation under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities, such as deferred revenue, relating to contracts with customers that are acquired in a business combination. Under existing guidance, an acquirer generally recognizes assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at their acquisition-date fair values in accordance with ASC Subtopic 820-10, Fair Value Measurements—Overall. Generally, this new guidance will result in the acquirer recognizing acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree prior to the acquisition under ASC Topic 606. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the impact of adopting this standard on our consolidated financial statements.

There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of demand or supply trends, financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2021 Annual Report and include but are not limited to:

- the effects of the COVID-19 pandemic on our business, financial condition and results of operations;
- the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market, economic conditions or COVID-19 pandemic;
- the extent to which a spike in the COVID-19 pandemic may disrupt our operations due to the unavailability of our employees or healthcare professionals because of illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, desire to travel and work on temporary assignments or other factors that limit our existing or potential workforce and pool of candidates;
- the severity and duration of the impact the COVID-19 pandemic has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered;
- the effects of economic downturns, inflation, recession or slow recoveries, which could result in less demand for our services, pricing pressures and negatively impact payments terms and collectability of accounts receivable;
- any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including mandatory vaccination requirements;
- the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts;
- the level of consolidation and concentration of buyers of healthcare workforce, staffing and technology solutions, which could affect the pricing of our services and our ability to mitigate concentration risk;
- the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, telemedicine or otherwise, which may negatively affect our revenue, results of operations, and cash flows;
- any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;
- any inability on our part to grow and operate our business profitably in compliance with federal and state regulation, including privacy laws, conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting;
- any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
- the effect of investigations, claims, and legal proceedings alleging medical malpractice, anti-competitive conduct, violations of employment, privacy and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
- any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and ability to manage our business effectively;
- any failure to further develop and evolve our current workforce solutions technology offerings and capabilities, which may harm our business and/or impact our ability to compete with new technologies and competitors;
- disruption to or failures of our SaaS-based or technology-enabled services, or our inability to adequately protect our intellectual property rights with respect to such technologies or sufficiently protect the privacy of personal information, could reduce client satisfaction, harm our reputation and negatively affect our business;
- security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities;
- any inability on our part to quickly and properly credential and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;
- any inability on our part to continue to attract, develop and retain our sales and operations team members, which may deteriorate our operations;
- our increasing dependence on third parties, including offshore vendors, for the execution of certain critical functions;
- the loss of our key officers and management personnel, which could adversely affect our business and operating results;
- any inability to consummate and effectively incorporate acquisitions into our business operations, which may adversely affect our long-term growth and our results of operations;
- businesses we acquire may have liabilities or adverse operating issues, which could harm our operating results;
- any increase to our business and operating risks as we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of client solutions;
- any inability on our part to maintain our positive brand awareness and identity, which may adversely affect our results of operation;
- the expansion of social media platforms presents new risks and challenges, which could cause damage to our brand reputation;
- any recognition of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;
- our indebtedness, which could adversely affect our ability to raise additional capital to fund operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt;
- the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and
- the effect of significant adverse adjustments to our insurance-related accruals on our balance sheet, which could decrease our earnings or increase our losses and negatively impact our cash flows.

## Market risk

As filed, 753 characters.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and six months ended June 30, 2022, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. During the three and six months ended June 30, 2022, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

## Controls and procedures

As filed, 1,197 characters.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of June 30, 2022 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 501 characters.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2021 Annual Report. The risk factors described in our 2021 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows.

Filed Aug 5, 2022.
Source: SEC EDGAR, the filing index for accession 0001142750-22-000023. Last ingested by Listed: Nov 5, 2026, 17:59 ET. No prices; not investment advice.
